Com­pa­nies ask FDA for reg­u­la­tion, im­prove­ment of da­ta col­lec­tion from dig­i­tal health de­vices

The FDA should con­sid­er reg­u­lat­ing how da­ta gath­ered from dig­i­tal health de­vices like con­tin­u­ous glu­cose mon­i­tors and sen­sors are in­cor­po­rat­ed in­to clin­i­cal-tri­al sub­mis­sions, ac­cord­ing to sev­er­al com­ment let­ters from mul­ti­ple ad­vo­cate and in­dus­try or­ga­ni­za­tions.

At least five or­ga­ni­za­tions have sub­mit­ted pub­lic com­ments on the FDA’s pro­pos­al ex­am­in­ing how best to use dig­i­tal health tech­nolo­gies (DHTs) in drug and bi­o­log­ic de­vel­op­ment, par­tic­u­lar­ly in de­cen­tral­ized clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER